Sciencast Management LP Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Sciencast Management LP purchased a new position in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 9,630 shares of the medical equipment provider’s stock, valued at approximately $694,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HOLX. FMR LLC grew its stake in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Boston Partners grew its stake in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after buying an additional 1,602,463 shares in the last quarter. Nordea Investment Management AB grew its stake in Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Hologic in the 4th quarter worth approximately $27,007,000. Finally, Swedbank AB boosted its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.8 %

Shares of NASDAQ HOLX opened at $61.47 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The firm has a market capitalization of $13.79 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The firm has a fifty day simple moving average of $66.06 and a two-hundred day simple moving average of $73.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of research reports. Morgan Stanley cut their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Wolfe Research initiated coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Royal Bank of Canada cut their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.